The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
Updated: RFK Jr. advances out of Senate committee with Cassidy’s support
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
February 5, 2025